Drug intelligence / Profile preview

CMR316

Development stage: Phase 1
Lead developer: Calibr-Skaggs Institute for Innovative Medicines
Modality: Small Molecules
Administration: Inhalation

Overview

CMR316 is a first-in-class inhaled DPP4 inhibitor designed to stimulate lung stem cells to regenerate damaged lung tissue. It specifically targets type 2 alveolar epithelial cells (AEC2s) in the lung, promoting their expansion and the formation of new lung cells responsible for gas exchange. The drug was chemically modified to have low membrane permeability, allowing it to engage DPP4 specifically in the lung lumen. It is administered once weekly via nebulization at very low doses (1-2 mg).

Targets

DPP-4 (Dipeptidyl Peptidase-IV)

Beyond the preview

Go deeper on CMR316.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CMR316.

Explore the full profile